<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background/Aims: TGF-β has dual functions as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> promoter or a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies suggest the roles of TGF-β might change from a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor to a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> promoter, when lacking SMAD4 expression in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (<z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>However, the precise role of TGF-β as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> promoter in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> is still unclear </plain></SENT>
<SENT sid="3" pm="."><plain>Methodology: We evaluated the role of TGF-β in SMAD4-null <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> SW620 cells </plain></SENT>
<SENT sid="4" pm="."><plain>In vitro, we measured cell growth and cell cycle distribution by flow cytometry </plain></SENT>
<SENT sid="5" pm="."><plain>In vivo, we implanted SW620 cells into mice and measured <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> weight after TGF-β treatment </plain></SENT>
<SENT sid="6" pm="."><plain>We also determined cell proliferation ability in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> by immunohistochemistry of proliferating cell nuclear antigen (PCNA) </plain></SENT>
<SENT sid="7" pm="."><plain>Results: Cell growth and DNA synthesis in S phase was remarkably enhanced by TGF-β in vitro </plain></SENT>
<SENT sid="8" pm="."><plain>Besides, TGF-β-activated ERK1/2 MAPK signal was also observed </plain></SENT>
<SENT sid="9" pm="."><plain>In vivo, TGF-β enhanced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and cell proliferation in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Conclusions: TGF-β serves as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> promoter, which promotes <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell growth in vitro and in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>These suggest that TGF-β might be developed as an effective therapeutic target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>